Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION)

This study is currently recruiting participants.
Verified March 2011 by University of Calgary
Sponsor:
Collaborator:
Heart and Stroke Foundation of Canada
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT00867984
First received: March 20, 2009
Last updated: March 31, 2011
Last verified: March 2011

March 20, 2009
March 31, 2011
March 2009
July 2012   (final data collection date for primary outcome measure)
Improved functional class (≥ 1 class) & remodeling (either ≥ 10% relative reduction in LV ESV or a ≥ 5% absolute increase in LV EF). [ Time Frame: Follow up (3-6 months) versus baseline. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00867984 on ClinicalTrials.gov Archive Site
  • dyssynchrony and torsion [ Time Frame: Follow-up (3-6 months) vs. baseline ] [ Designated as safety issue: No ]
  • mitral regurgitation [ Time Frame: Follow-up (3-6 months) vs. baseline ] [ Designated as safety issue: No ]
  • N-terminal BNP level [ Time Frame: Follow-up (3-6 months) vs. baseline ] [ Designated as safety issue: No ]
  • quality of life [ Time Frame: Follow-up (3-6 months) vs. baseline ] [ Designated as safety issue: No ]
Same as current
 
 
 
Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders
Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION). A Randomized Comparison of Torsion-imaging Guided Optimization vs. Usual Settings.

Approximately 40% of resynchronization therapy recipients do not appear to clearly benefit. These patients are termed 'non-responders'. This study will assess whether a heart ultrasound (echo) technique called 'torsion imaging' can be used to increase the likelihood of benefit from resynchronization therapy.

Background: Despite advances in pharmacotherapy, patients with heart failure (HF) are at high risk for death and hospitalization. Over 25% of patients with systolic HF have dyssynchronous ventricular contraction that impairs left ventricular (LV) function and results in HF progression. Cardiac resynchronization therapy (CRT) is designed to synchronize ventricular mechanical activity, improving cardiac output and reducing HF symptoms. As shown in our pilot data, at least 40% of patients do not respond to CRT despite pre-screening for the presence of longitudinal (long axis) mechanical (velocity) dyssynchrony and targeting LV lead placement to the latest site of latest velocity. Methods to improve the rates of response to CRT are required. Torsion imaging guided optimization of CRT timing is a promising approach and will be tested in this study.

Primary hypothesis: Optimization of inter-ventricular (VV) timing, guided by torsion imaging, will increase functional capacity and reduce LV end systolic volume [ESV] in CRT in patients who have not responded after ≥ 6 months. CRT response will be defined by a ≥ 1 functional class improvement and either a ≥ 10% reduction in LV ESV or a ≥ 5% increase in EF at follow-up versus baseline.

Secondary aims: To compare the following in torsion-guided vs usual care patients: a) echo parameters (intra-LV and VV dyssynchrony and torsion, and mitral regurgitation), b) N-terminal BNP levels, and c) generic / disease-specific quality of life.

Methods: Randomized study of patients who have not responded to CRT after ≥ 6 months.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Heart Failure, Congestive
  • Other: Torsion optimized
    Torsion optimized VV timing plus AV optimization (VTI)
  • Other: Usual Care
    AV optimization (VTI) only
  • Experimental: 1
    Torsion-guided VV optimization plus AV optimization.
    Intervention: Other: Torsion optimized
  • Active Comparator: 2
    AV optimization only.
    Intervention: Other: Usual Care
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • non-response to CRT as indicated,
  • stable doses of ACE I / ARB and beta-blocker for ≥ 2 months, &
  • controlled heart rate if in atrial fibrillation.

Exclusion Criteria:

  • inadequate images to assess torsion
  • no significant augmentation in torsion with optimization
  • unable or unwilling to provide informed consent,
  • medical condition other than HF likely to cause death within 6 months,
  • cardiac transplant planned,
  • myocardial infarction or revascularization since CRT implant.
Both
18 Years and older
No
Contact: Derek V Exner, MD, MPH 403.220.3219 exner@ucalgary.ca
Contact: Karen Cowan, RN 403.220.2217 kcowan@ucalgary.ca
Canada
 
NCT00867984
7345220000
Yes
Derek Exner, University of Calgary
University of Calgary
Heart and Stroke Foundation of Canada
Principal Investigator: Derek V Exner, MD, MPH University of Calgary
University of Calgary
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP